Back

Evaluation of the effect of oral anticoagulants on all-cause mortality within 3 months of the diagnosis of atrial fibrillation: results from the GARFIELD-AF prospective registry

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Atrial fibrillation - Stroke prevention - General Oral Anticoagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Ms Karen Pieper

Thrombosis Research Institute, London (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation: a propensity-weighted cohort study
Associate Professor E. Grove (Aarhus, DK)
Abstract Slides
Presentation thumbnail
Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF
Professor G. Lip (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Impact of age > 75 years on one-year events in patients with atrial fibrillation and left atrial appendage occluder implantation. Results of the prospective LAARGE Registry
Professor U. Zeymer (Ludwigshafen, DE)
Abstract
Presentation thumbnail
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study
Doctor X. Li (Princeton, US)
Abstract Slides
Presentation thumbnail
Stroke, thromboembolism and bleeding events in patients with atrial fibrillation according to the new EHRA valvular heart disease classification
Doctor A. Bisson (Tours, FR)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Atrial fibrillation - Stroke prevention - General

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources